← All trials
NCT05506137
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Feb 28, 2025
- Completion date
- Jun 30, 2025
- First posted
- Aug 18, 2022
- Last posted
- Aug 18, 2022
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Maastricht UniversityLead sponsor
- ZonMw: The Netherlands Organisation for Health Research and DevelopmentCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.